Comparison of three similar frontline breast cancer drugs reveals important differences

First head-to-head comparison of CDK4/6 inhibitors in cell line and animal models of breast cancer reveals important differences, including one drug that exhibits unique, potentially advantageous therapeutic activity.

Leave a Reply

Your email address will not be published. Required fields are marked *